Lacosamida Krka

Lacosamide, the active ingredient in Lacosamida Krka, is a sodium channel blocker presented as an oral dosage form for oral use. It is indicated for the treatment of partial‑onset and focal onset seizures in patients requiring anticonvulsant therapy.

GNH USA supplies Lacosamida Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamida Krka is an anticonvulsant that targets neuronal sodium channels to control seizure activity.

- Partial‑onset seizures: reduces the frequency and severity of seizures that originate in one area of the brain. - Focal onset seizures: helps achieve seizure control in patients with focal seizure patterns. - Adjunctive therapy: can be added to existing antiepileptic regimens to improve overall seizure management.

Lacosamida Krka may cause a range of adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: increased tiredness or lack of energy. - Nausea: feeling of stomach upset or urge to vomit. - Headache: mild to moderate cranial pain. - Diplopia: transient double vision. - Somnolence: tendency to feel sleepy.

Serious or Rare Side Effects: - Suicidal thoughts: emergence of depressive ideation or self‑harm urges. - Severe rash: skin reactions such as Stevens‑Johnson syndrome. - Cardiac arrhythmia: irregular heart rhythm, including PR‑interval prolongation. - Respiratory depression: reduced breathing effort. - Allergic reactions: anaphylaxis or severe hypersensitivity. - Blood dyscrasias: abnormal blood cell counts, such as agranulocytosis.

Before initiating therapy with Lacosamida Krka, clinicians should consider several safety measures.

- Renal function monitoring: assess kidney function periodically, especially in patients with impairment. - Hepatic function assessment: evaluate liver enzymes before and during treatment. - CNS depressant review: avoid concomitant use with other central nervous system depressants without careful monitoring. - Driving counseling: advise patients about potential dizziness and somnolence affecting motor skills. - Discontinuation guidance: do not stop abruptly; taper under medical supervision to prevent seizure recurrence. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamida Krka can interact with several medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce lacosamide exposure. - Other sodium channel blockers (e.g., carbamazepine): additive risk of cardiac conduction effects. - Alcohol: potentiates central nervous system depression.

Moderate Interactions (Monitor Closely): - Anticonvulsants such as valproate: may require dosage adjustments. - Hormonal contraceptives: lacosamide may reduce contraceptive effectiveness. - Antidepressants (e.g., SSRIs): monitor for increased dizziness or sedation.